2024 ESMO IO | 超60项中国研究入选，中国强音继续响彻国际舞台
更新时间：2024-10-30 20:02 浏览量：79
前言
2024年欧洲肿瘤内科学会免疫肿瘤大会（ESMO IO）将于当地时间12月11日~13日在瑞士日内瓦召开。各领域肿瘤大咖将齐聚日内瓦共探免疫疗法的最新前沿成果，以进一步推动临床肿瘤学的发展。目前大会官网已披露了摘要标题（除LBA摘要外），我国学者共有62项研究入选，医脉通特整理如下，和读者一起抢先体验即将奏响的中国强音。Mini Oral session
01 摘要号：67MO
Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab in patients with MSS/pMMR locally advanced rectal cancer - A multicentre phase II trial ( mRCAT)
淋巴结豁免的改良短程放疗联合CAPOX和替雷利珠单抗治疗局部晚期MSS/pMMR直肠癌患者——一项多中心II期试验（mRCAT）
讲者：Zhangfa Song 中国杭州
02 摘要号：171MO
Unraveling iCAF and Tumor Cell Communication: Advancing Novel Adjuvant Immunotherapy Response and Prognostic Prediction via Single-Cell Analysis and Multimodal data-based Models
阐述iCAF和肿瘤细胞通讯：通过单细胞分析和多模式数据模型推进新辅助免疫治疗的应答和预后预测
讲者：Wei Ren 中国广州
Poster Display session
01 摘要号：7P
ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
ACOX2干扰MRE11-RAD50-NBS1复合物的稳定性，并在透明细胞肾细胞癌中激活免疫肿瘤微环境
讲者：Shiqi Ye 中国上海
02 摘要号：21P
Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
TP53突变亚型在肿瘤抗PD-(L)1免疫治疗中对疗效的影响
讲者：Lige Wu 中国北京
03 摘要号：43P
Machine learning radiomics based on CT to predict response to lenvatinib plus Tislelizumab based therapy for unresectable hepatocellular carcinoma
基于CT的机器学习放射组学预测不可切除肝细胞癌接受仑伐替尼/联合替雷利珠单抗的应答
讲者：Gang Chen 中国温州
04 摘要号：45P
Gut Microbiome Signatures for Exploring the Correlation Between Gut Microbiome and Immune Therapy Response Using Machine Learning Approach
使用机器学习探索肠道微生物组与免疫治疗应答相关性的肠道微生物组特征
讲者：Han Li 中国济南
05 摘要号：46P
Abnormal Gut Microbiota May Cause PD-1 Inhibitor-Related Cardiotoxicity via Suppressing Regulatory T Cells
肠道微生物群异常可能通过抑制调节性T细胞导致PD-1抑制剂相关的心脏毒性
讲者：Zeeshan Afzal 中国太原
06 摘要号：51P
Unlocking CAR-T Cell Potential: Lipid Metabolites in Overcoming Exhaustion in Ovarian Cancer
释放CAR-T细胞潜力：脂质代谢产物在克服卵巢癌衰竭中的作用
讲者：Xiangyu Chang 中国北京
07 摘要号：62P
Ecto-CRT induction of NKp46 surface expression increases Osimertinib-resistant lung cancer’s sensitivity to NK cell
Ecto-CRT诱导NKp46的细胞表面表达并增加奥希替尼耐药性肺癌对NK细胞的敏感性
讲者：Sumei Chen 中国杭州
08 摘要号：63P
Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
单细胞RNA测序与转录组RNA测序联合显示胰腺癌组织抑制性巨噬细胞参与肿瘤进展和免疫治疗应答
讲者：BIN Wu 中国嘉兴
09 摘要号：70P
Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
PD-1阻断剂联合化疗治疗恶性非小细胞肺癌的疗效
讲者：Haowei Wang 中国上海
10 摘要号：75P
Real-world Data of Adebrelimab in the First-line Treatment of Patients with Small-cell Lung Cancer
阿得贝利单抗应用于小细胞肺癌患者一线治疗中的真实世界数据
讲者：Yong Song 中国连云港
11 摘要号：78P
Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study
甲胎蛋白结合初始肿瘤轮廓不规则性预测晚期肝细胞癌患者接受免疫治疗的生存率：一项回顾性多中心队列研究
讲者：Yong-Shuai Wang 中国合肥
12 摘要号：82P
Predictive Biomarkers for Neoadjuvant Immunochemotherapy Efficacy in Locally Advanced Cancer Patients: A Retrospective Analysis Based on Changes in Tumor Shrinkage Rate and Lymphocyte Count
新辅助免疫化疗应用于局部晚期肿瘤的疗效预测性生物标志物：基于肿瘤退缩率和淋巴细胞计数变化的回顾性分析
讲者：Zhanjie Zhang 中国武汉
13 摘要号：83P
Effectiveness and Safety of Neoadjuvant Immunochemotherapy with and without Surgery in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study
可切除食管鳞状细胞癌患者手术前后新辅助免疫化疗的有效性和安全性：一项回顾性队列研究
讲者：Xuqiang Liao 中国海口
14 摘要号：85P
Impact of Serum Lipid Levels on Immune Therapy-Related Hepatotoxicity in Patients with Pan-cancer: A Cohort Study
血脂水平对泛癌患者免疫治疗相关肝毒性的影响：一项队列研究
讲者：Lei Jing 中国上海
15 摘要号：89P
Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: a systematic review and meta-analysis
晚期实体瘤接受免疫检查点抑制剂再挑战的安全性和有效性：系统评价和荟萃分析
讲者：Hui J. Xu 中国合肥
16 摘要号：92P
An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
鼻咽癌患者治疗前营养和免疫状况与健康人群差异的调查
讲者：Qiao He 中国成都
17 摘要号：102P
A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
不可切除肝细胞癌二线治疗的真实世界研究：一线使用仑伐替尼联合PD-1抑制剂后进展的患者的疗效
讲者：Saifeng Li 中国南昌
18 摘要号：103P
Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma -A multicenter, prospective, single-arm, real-world study
替雷利珠单抗联合放化疗治疗局部晚期食管鳞状细胞癌——多中心、前瞻性、单臂真实世界研究
讲者：Zhihua Wen 中国济南
19 摘要号：104P
The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
新型PD-1/CTLA-4双特异性抗体卡度尼利单抗（AK104）作为转移性非小细胞肺癌的二线或后续治疗的疗效和安全性
讲者：Hualin Chen 中国广东
20 摘要号：105P
A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
一项回顾性研究，使用机器学习分析VEGFR-TKI和PD-1抑制剂作为三线或后续治疗在MSS mCRC患者中的效果
讲者：Shumei Han 中国济南
21 摘要号：107P
Efficacy and Safety of First-line TKI Plus ICI Therapy in Metastatic Non-clear Cell Renal Cell Carcinoma: A Real-world Multiple-centre Study
晚期非透明细胞肾细胞癌中一线TKI联合ICI治疗的疗效和安全性：真实世界多中心研究
讲者：Yulu Peng 中国广州
22 摘要号：108P
Transarterial Chemoembolization (TACE) Combined With Atezolizumab And Bevacizumab Versus TACE Alone In Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score-Matched Analysis
经动脉化疗栓塞（TACE）联合阿替利珠单抗和贝伐珠单抗对比单独TACE在BCLB B期不可切除肝细胞癌患者中的应用：回顾性倾向评分匹配分析
讲者：Hongjie Cai 中国广州
23 摘要号：109P
Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
针对非小细胞肺癌（NSCLC）中无驱动基因的脑转移患者一线免疫联合系统治疗和脑放疗的疗效
讲者：Mengxing You 中国北京
24 摘要号：110P
Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: a prospective, real-world study
在广泛期小细胞肺癌中作为一线治疗的阿得贝利单抗的安全性和有效性：一项前瞻性真实世界研究
讲者：Junxu Wen 中国济南
25 摘要号：111P
Real-world treatment patterns and clinical outcomes in Chinese stage III Non-small Cell Lung Cancer (NSCLC) patients: results of MOOREA study
中国III期非小细胞肺癌患者的真实世界治疗模式和临床结果：MOOREA研究结果
讲者：Ligang Xing 中国济南
26 摘要号：112P
Serplulimab Combined with Chemotherapy and Anlotinib for Extensive-stage Small-cell Lung Cancer: a Multicenter Real-world Experience
斯鲁利单抗联合化疗和安罗替尼用于广泛期小细胞肺癌：多中心真实世界经验
讲者：Jun Wang 中国石家庄
27 摘要号：114P
Cadonilimab plus chemotherapy as first-line (1L) treatment for metastatic gastric (G) or gastroesophageal junction adenocarcinoma (GEJA) with PD-L1 CPS≤5：Updated results from a real-world study
卡度尼利单抗加化疗作为PD-L1 CPS≤5的转移性胃或食管交界腺癌的一线（1L）治疗：来自真实世界研究的更新结果
讲者：Qi Xu 中国杭州
28 摘要号：116TiP
An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
一项伞式试验（RECHALLENGE）评估在临床试验进展后先进实体肿瘤患者中联合或序贯免疫疗法的安全性和初步疗效
讲者：Hui-lei Miao 中国北京
29 摘要号：125P
Enhancing the Efficacy of Neoantigen Tumor Vaccines in Melanoma Treatment through Different Administration Times
通过不同给药时间增强黑色素瘤治疗中的新抗原肿瘤疫苗的疗效
讲者：Kai Xiao 中国成都
30 摘要号：130P
Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: preliminary results from a phase II trial
在dMMR/MSI-H局部晚期结直肠癌中的新辅助治疗：一项II期试验的初步结果
讲者：Caifeng Gong 中国北京
31 摘要号：131P
The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
卡度尼利单抗联合或不联合曲妥珠单抗及SOX作为晚期胃或食管交界腺癌的一线（1L）治疗的疗效和安全性
讲者：Wenhui Yang 中国太原
32 摘要号：132P
An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
一项开放标签的前瞻性II期研究，评估卡度尼利单抗与新辅助化疗联合治疗晚期卵巢癌患者（AK104-IIT-003）
讲者：Jie Tang 中国长沙
33 摘要号：133P
The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: a single-arm, open-label, multicenter phase 2 clinical trial.
KN046联合阿昔替尼用于既往未经治疗及经免疫检查点抑制剂治疗的晚期非小细胞肺癌的疗效和安全性：单臂开放标签多中心II期临床试验
讲者：Li Zhang 中国广州
34 摘要号：134P
Intracranial (IC) Progression-Free Survival (PFS) with Ivonescimab (Ivo) Compared to Placebo in the HARMONi-A Trial of Patients (Pts) with Previously Treated EGFR Mutation-Positive (EGFRm+) Non-Small Cell Lung Cancer (NSCLC)
HARMONi-A试验中依沃西单抗（Ivo）对比安慰剂在先前治疗的EGFR突变阳性（EGFRm+）非小细胞肺癌（NSCLC）患者中的颅内（IC）无进展生存期（PFS）
讲者：杨Li Zhang 中国广州
35 摘要号：135P
Efficacy and safety of Tislelizumab combined with Bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): a prospective, single-arm Phase II clinical study
替雷利珠单抗联合支气管动脉灌注（BAI）化疗在潜在可切除IIIB期非小细胞肺癌（NSCLC）患者中的疗效和安全性：前瞻性单臂II期临床研究
讲者：Xu Ma 中国上海
36 摘要号：136P
Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: an updated analysis
替雷利珠单抗（T）联合化疗（chemo）联合或不联合贝伐珠单抗（beva）用于EGFR突变的非鳞状NSCLC患者（nsq-NSCLC）在EGFR TKI治疗后进展的患者中的更新分析
讲者：韩宝惠 上海交通大学附属胸科医院
37 摘要号：137P
Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Tislelizumab for Unresectable Hepatocellular Carcinoma: A Single-arm, Phase II Study
肝动脉灌注化疗联合仑伐替尼和替雷利珠单抗治疗不可切除肝细胞癌：单臂II期研究
讲者：Jianbing Wu 中国南昌
38 摘要号：138P
Interim results of Neoadjuvant TACE Plus Lenvatinib and Tislelizumab in Resectable HCC at CNLC Stages IB and IIA with High-risk of recurrence: A Prospective, Single-Arm, Phase II Trial
对CNLC IB期和高复发风险IIA期可切除肝细胞癌患者，新辅助TACE联合仑伐替尼和替雷利珠单抗的中期结果：前瞻性单臂II期试验
讲者：Yuhua Zhang 中国杭州
39 摘要号：139P
Ablation combined with tislelizumab in treating hepatocellular carcinoma: a phase II trial
消融联合替雷利珠单抗治疗肝细胞癌的II期试验
讲者：Yangxun Pan 中国广州
40 摘要号：140P
Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective ,single-arm, phase 2 study
替雷利珠单抗联合仑伐替尼和经动脉化疗栓塞（TACE）新辅助治疗可切除的CNLC IIa-IIb肝细胞癌：前瞻性单臂II期研究
讲者：Zhibo Zhang 中国福州
41 摘要号：141P
Efficacy and safety of Tislelizumab(T) combined with Gemcitabine and Cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: a prospective, phase II study
替雷利珠单抗（T）联合吉西他滨和顺铂（GC）用于根治性局部手术后局部肌层浸润性膀胱癌（MIBC）患者的疗效和安全性：前瞻性II期研究
讲者：Ming Cao 中国上海
42 摘要号：145P
Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
基于派安普利单抗的新辅助/辅助联合治疗用于可切除的局部晚期非小细胞肺癌患者：II期前瞻性研究（ALTER-L043）的更新结果
讲者：Changli Wang 中国天津
43 摘要号：146P
Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: a single-arm, single-center, phase II clinical trial
新辅助阿得贝利单抗联合化疗治疗食管胃交界腺癌：单臂、单中心II期临床试验
讲者：Jinqiang Liu 中国西安
44 摘要号：147P
Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trial
斯鲁利单抗联合化疗在可切除食管鳞状细胞癌的新辅助治疗中的应用：单臂II期试验
讲者：Zixiang Wu 中国杭州
45 摘要号：148P
Neoadjuvant Camrelizumab plus Metronomic Chemotherapy in Patients with advanced esophageal squamous cell carcinomas：a randomized phase 2 trial
新辅助Camrelizumab加代谢化疗用于晚期食管鳞状细胞癌患者：随机II期试验
讲者：JIE LIU 中国上海
46 摘要号：149P
Toripalimab and Chemotherapy as First Line Combination in Advanced Thymic Carcinoma: A Prospective, Single-Arm, Phase II Trial
特瑞普利单抗与化疗联合作为晚期胸腺癌的一线治疗：前瞻性单臂II期试验
讲者：Kai Zhu 中国北京
47 摘要号：153P
Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): preliminary results from a phase 2 study
针对免疫治疗耐药的复发/转移性鼻咽癌（R/M NPC）患者，Tim-3阻断剂TQB2618联合PD-1阻断剂的初步结果：II期研究
讲者：Cheng Xu 中国广州
48 摘要号：180P
Chronic circadian disruption promotes melanoma progression by interfering with NK cells
慢性昼夜节律破坏通过干扰NK细胞促进黑色素瘤进展
讲者：Shuwen Xiao 中国成都
49 摘要号：186P
Unveil and overcome PD(L)1 antibody resistance via functional genomics and clinical derived biopsies
揭示并克服PD-(L)1抗体耐药性：通过功能基因组学和临床衍生活检
讲者：BIN XIE 中国上海
50 摘要号：187P
Single-cell RNA sequencing elucidates the role of intercommunication between epithelial cells, immune cells, and fibroblasts in high-grade serous ovarian cancer
单细胞RNA测序阐明上皮细胞、免疫细胞和成纤维细胞在高级别浆液性卵巢癌中的相互作用
讲者：Xiaoting Zhao 中国北京
51 摘要号：188P
Single-cell and Spatial Transcriptomics Delineate the Microstructure and Immune Landscape of Intrahepatic Cholangiocarcinoma in the Leading-edge Area
单细胞和空间转录组学描绘肝内胆管癌前沿区域的微结构和免疫微环境
讲者：Zuyin Li 中国北京
52 摘要号：189P
Image-guided Labeling of Live Cells in TLS for Single Cell Transcriptomics
活细胞在TLS中的图像引导标记，用于单细胞转录组学
讲者：Mengrui Cao 中国北京
53 摘要号：199P
Cancer Neutrophil Encyclopedia: A Deep Dive into Antigen-Presenting Warriors
肿瘤中性粒细胞百科全书：深入探讨抗原呈递战士
讲者：Yingcheng Wu 中国上海
54 摘要号：200P
CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
CXCR1+中性粒细胞浸润调控EGFR突变非小细胞肺癌中第三代EGFR-TKI的反应
讲者：Haowei Wang 中国上海
55 摘要号：203P
Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
靶向IL-33重塑肿瘤微环境并增强抗肿瘤反应，对抗PD-L1免疫疗法
讲者：Xuyao Zhang 中国上海
56 摘要号：207P
ZEB2 inhibition relieves TAMs-mediated immunosuppression in EGFR-TKI resistant NSCLC
ZEB2抑制缓解EGFR-TKI耐药非小细胞肺癌中，肿瘤相关巨噬细胞介导的免疫抑制
讲者：Yunhuan Liu 中国上海
57 摘要号：211P
Single-cell Characterization of Differentiation Trajectories and Drug Resistance Features in Gastric Cancer with Peritoneal Metastasis
单细胞表征腹膜转移胃癌的分化轨迹和耐药特征
讲者：Haoxin Peng 中国北京
58 摘要号：212P
YAP/TEAD4/SP1-induced VISTA expression as a tumor cell-intrinsic mechanism of immunosuppression in colorectal cancer
YAP/TEAD4/SP1诱导的VISTA表达作为结直肠癌中的肿瘤细胞内在免疫抑制机制
讲者：Zhehui Zhu 中国上海
59 摘要号：217P
Tumor-derived CCL15 regulates RNA m6A methylation in cancer-associated fibroblasts to promote hepatocellular carcinoma growth
肿瘤来源的CCL15调控癌症相关成纤维细胞中的RNA m6A甲基化，促进肝细胞癌生长
讲者：Yueguo Li 中国天津
60 摘要号：220P
Correlation research between oral flora diversity radiation-induced stomatitis after postoperative radiotherapy for oral squamous cell carcinoma
口腔微生物多样性与放射治疗后口腔鳞状细胞癌术后放射性口腔炎之间的相关性研究
讲者：Qin Zheng 中国南京
备注：排名不分先后，按照摘要号进行排序
如有遗漏或任何问题，请给我们留言~
撰写：Babel
排版：Babel
执行：Squid
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。